IMNM

Business Context and Reporting Period

Immunome, Inc. (IMNM) is a biotechnology company developing targeted oncology therapies, specifically antibody-drug conjugates (ADCs) and other modalities. This Form 10-Q covers the quarterly period ended March 31, 2026. The company operates as a single segment focused on the discovery, design, and development of oncology therapeutics. As of the reporting date, the company has not generated any product revenue and remains in a pre-commercial stage, relying on equity financing and collaboration agreements to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Collaboration revenue dropped to zero in Q1 2026 compared to $2.9 million in Q1 2025. The collaboration agreement with AbbVie terminated in July 2025, and all associated revenue was recognized by June 30, 2025.
• Increased Operating Expenses: Total operating expenses rose by $11.8 million (25%) year-over-year. Research and Development (R&D) expenses increased by $9.5 million, driven by higher personnel costs, share-based compensation, and IND-enabling activities for new programs (IM-1021, IM-3050, IM-1617), partially offset by a decrease in clinical trial costs for varegacestat following its Phase 3 readout.
• Liquidity Position: Cash and cash equivalents increased significantly to $582.7 million from $257.6 million in the prior year, bolstered by public equity offerings in January and December 2025 totaling approximately $594 million in net proceeds.
• Net Loss Expansion: Net loss increased by $12.2 million to $53.8 million, primarily due to the cessation of collaboration revenue and increased R&D spending, partially mitigated by higher interest income ($5.5 million vs. $3.0 million).

Guidance, Outlook, and Risks

Outlook and Pipeline:

• Varegacestat: The company submitted a New Drug Application (NDA) to the FDA in April 2026 following positive Phase 3 RINGSIDE trial results for desmoid tumors. A Marketing Authorization Application (MAA) to the EMA is planned for late 2026.
• ADC Pipeline: IM-1021 (ROR1 ADC) is in Phase 1 with data expected in 2026. IM-3050 (FAP radioligand therapy) initiated Phase 1 in March 2026. IM-1617 received IND clearance in April 2026 with Phase 1 initiation planned for Q2 2026.
• Liquidity Runway: Management expects existing cash resources to fund operations and capital expenditures for at least 12 months from the filing date (May 2026).

Risks and Contingencies:

• Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require additional financing to support commercialization of varegacestat and development of the pipeline. Future funding may come from equity offerings (including an existing ATM agreement with $134.1 million remaining), debt, or collaborations.
• Regulatory Risk: There is no guarantee that the NDA for varegacestat will be approved or that other candidates will successfully progress through clinical trials.
• Third-Party Reliance: The company relies on third-party vendors for manufacturing and clinical trials, creating supply chain and execution risks.
• Intellectual Property: The company faces risks related to patent protection, potential infringement claims, and the ability to defend its IP portfolio.

Investor Verification Checklist

• Verify the status and timeline of the FDA review for the varegacestat NDA submitted in April 2026.
• Confirm the specific burn rate and cash runway beyond the stated 12-month period, given the high cost of commercialization preparation.
• Review the terms of the Bristol-Myers Squibb (BMS) license agreement regarding milestone payments and royalty obligations for varegacestat and AL101.
• Assess the progress of Phase 1 trials for IM-1021, IM-3050, and IM-1617, particularly regarding patient enrollment and safety data.
• Monitor the utilization of the "at-the-market" (ATM) equity offering facility and any potential dilution from future capital raises.